FREMONT, Calif. — Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that Linda Ramirez will join the Company as Chief Legal Officer. Linda has nearly 30 years of experience practicing law, with over a decade in the life sciences and biotechnology industry. Before joining Ultima, Linda was the General Counsel of Olink, a leading provider of next-generation proteomics solutions. Linda led Olink through a successful initial public offering on the Nasdaq and subsequent rounds of fundraising, culminating in its 2024 acquisition by Thermo Fisher Scientific for approximately $3.1 billion.

“Linda is an accomplished leader and has a wealth of valuable experience leading emerging companies through commercial launch, multiple financings, including an IPO, as well as large strategic and commercial partnerships,” said Gilad Almogy, CEO of Ultima. “While serving as General Counsel at Olink, Linda led many of the Company’s most important commercial and strategic partnerships, in addition to leading the Company through an IPO and the acquisition by Thermo Fisher Scientific. As Ultima’s commercial momentum and partnership activity continues to accelerate, Linda will play a pivotal role in advising Ultima through this next phase of growth.”

“Ultima is leading a true paradigm shift in genomics with the UG 100 sequencing platform and now UG 100 Solaris, making high throughput sequencing more accessible, scalable, and affordable than ever before,” said Linda Ramirez, Chief Legal Officer of Ultima. “The company is not only driving down the cost of sequencing to enable innovations like the $80 genome but also expanding what’s possible for large-scale, data-hungry applications across healthcare and research. It’s an incredibly exciting time to join Ultima as it accelerates commercial growth and delivers on the promise of its unique technology to power the next era of biological discovery.”

Linda is a native of Colorado. She earned her BS in Journalism and Mass Communications and a JD from the University of Colorado at Boulder.

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company’s mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com